{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:59:37Z","timestamp":1790024377356,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to evaluate the efficacy (short-term changes in surrogates of decongestion) and safety following the ambulatory administration of subcutaneous furosemide (SCF) in patients with WHF. Fifty-five ambulatory patients were treated with SCF administered by an elastomeric pump for at least 72 h. Surrogates of congestion were assessed at baseline, 72 h, and 30 days. Spot urinary sodium (uNa+) was assessed at baseline, 24-48-72 h, and 30 days. The median (IQI) of NT-proBNP and uNa+ at baseline was 5218 pg\/mL (2856-10878) and 68\u00b13 mmol\/L, respectively. Following administration of SCF (median dose of 100 mg\/daily), we found a sustained increase in uNa+ during the first 72 h of treatment compared to baseline, paralleled with evidence of decongestion at 72 h, and 30 days. No significant safety concerns were observed. SCF was an effective and safe diuretic strategy for outpatient congestion management.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s12265-021-10173-1","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T03:48:05Z","timestamp":1634096885000},"page":"644-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: a Real-World Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Jose","family":"Civera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Espriella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Santas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Conesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Villaescusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7119","authenticated-orcid":false,"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"27","key":"10173_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., Gonz\u00e1lez-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"European Heart Journal"},{"issue":"6","key":"10173_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ejhf.289","volume":"17","author":"A Mebazaa","year":"2015","unstructured":"Mebazaa, A., Yilmaz, M. B., Levy, P., Ponikowski, P., Peacock, W. F., Laribi, S., Ristic, A. D., Lambrinou, E., Masip, J., Riley, J. P., McDonagh, T., Mueller, C., deFilippi, C., Harjola, V. P., Thiele, H., Piepoli, M. F., Metra, M., Maggioni, A., McMurray, J., et al. (2015). Filippatos G. Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 17(6), 544\u2013558. https:\/\/doi.org\/10.1002\/ejhf.289","journal-title":"European Journal of Heart Failure"},{"issue":"3","key":"10173_CR3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ehf2.12677","volume":"7","author":"E Wierda","year":"2020","unstructured":"Wierda, E., Dickhoff, C., Handoko, M. L., Oosterom, L., Kok, W. E., de Rover, Y., de Mol, B. A. J. M., van Heerebeek, L., & Schroeder-Tanka, J. M. (2020). Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: A systematic review of the literature. ESC Heart Failure, 7(3), 892\u2013902. https:\/\/doi.org\/10.1002\/ehf2.12677","journal-title":"ESC Heart Failure"},{"issue":"3","key":"10173_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10741-018-9760-6","volume":"24","author":"ME Afari","year":"2019","unstructured":"Afari, M. E., Aoun, J., Khare, S., & Tsao, L. (2019). Subcutaneous furosemide for the treatment of heart failure: A state-of-the art review. Heart Failure Reviews, 24(3), 309\u2013313. https:\/\/doi.org\/10.1007\/s10741-018-9760-6","journal-title":"Heart Failure Reviews"},{"issue":"1","key":"10173_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2015.06.017","volume":"4","author":"LF Buckley","year":"2016","unstructured":"Buckley, L. F., Carter, D. M., Matta, L., Cheng, J. W., Stevens, C., Belenkiy, R. M., Burpee, L. J., Young, M. A., Weiffenbach, C. S., Smallwood, J. A., Stevenson, L. W., & Desai, A. S. (2016). Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Failure, 4(1), 1\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2015.06.017","journal-title":"JACC Heart Failure"},{"issue":"2","key":"10173_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens, W., Damman, K., Harjola, V. P., Mebazaa, A., Brunner-La Rocca, H. P., Martens, P., Testani, J. M., Tang, W. H. W., Orso, F., Rossignol, P., Metra, M., Filippatos, G., Seferovic, P. M., Ruschitzka, F., & Coats, A. J. (2019). The use of diuretics in heart failure with congestion - A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21(2), 137\u2013155. https:\/\/doi.org\/10.1002\/ejhf.1369","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10173_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.rec.2020.06.004","volume":"74","author":"R de la Espriella","year":"2021","unstructured":"de la Espriella, R., N\u00fa\u00f1ez, E., Ll\u00e0cer, P., Garc\u00eda-Blas, S., Ventura, S., N\u00fa\u00f1ez, J. M., S\u00e1nchez, R., F\u00e1cila, L., Vaquer, J. M., Bod\u00ed, V., Santas, E., Mi\u00f1ana, G., Mollar, A., N\u00fa\u00f1ez, G., Chorro, F. J., G\u00f3rriz, J. L., Sanchis, J., Bay\u00e9s-Genis, A., & N\u00fa\u00f1ez, J. (2021). Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction. Rev Esp Cardiol (Engl Ed), 74(7), 616\u2013623. English, Spanish. https:\/\/doi.org\/10.1016\/j.rec.2020.06.004","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10173_CR8","doi-asserted-by":"publisher","unstructured":"N\u00fa\u00f1ez, J., de la Espriella, R., Mi\u00f1ana, G., Santas, E., Ll\u00e1cer, P., N\u00fa\u00f1ez, E., Palau, P., Bod\u00ed, V., Chorro, F. J., Sanchis, J., Lup\u00f3n, J., & Bay\u00e9s-Gen\u00eds, A. (2021). Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. European Journal of Heart Failure. https:\/\/doi.org\/10.1002\/ejhf.2295","DOI":"10.1002\/ejhf.2295"},{"issue":"6","key":"10173_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J. G. F., Kozhuharov, N., Coats, A. J. S., Metra, M., Mebazaa, A., Ruschitzka, F., Lainscak, M., Filippatos, G., Seferovic, P. M., Meijers, W. C., Bayes-Genis, A., Mueller, T., Richards, M., & Januzzi, J. L. (2019). Jr; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 21(6), 715\u2013731. https:\/\/doi.org\/10.1002\/ejhf.1494","journal-title":"European Journal of Heart Failure"},{"issue":"8","key":"10173_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1177\/1049909112465795","volume":"30","author":"LB Farless","year":"2013","unstructured":"Farless, L. B., Steil, N., Williams, B. R., & Bailey, F. A. (2013). Intermittent subcutaneous furosemide: Parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic. American Journal of Hospice and Palliative Care, 30(8), 791\u2013792. https:\/\/doi.org\/10.1177\/1049909112465795","journal-title":"American Journal of Hospice and Palliative Care"},{"issue":"1","key":"10173_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bmjspcare-2012-000296","volume":"3","author":"J Galindo-Oca\u00f1a","year":"2013","unstructured":"Galindo-Oca\u00f1a, J., Romero-Mena, J., Castillo-Ferrando, J. R., Aguilera-Gonz\u00e1lez, C., Bernabeu-Wittel, M., & Ollero-Baturone, M. (2013). Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure. BMJ Supportive Palliative Care, 3(1), 7\u20139. https:\/\/doi.org\/10.1136\/bmjspcare-2012-000296","journal-title":"BMJ Supportive Palliative Care"},{"issue":"1","key":"10173_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jacbts.2017.10.001","volume":"3","author":"DA Sica","year":"2018","unstructured":"Sica, D. A., Muntendam, P., Myers, R. L., Ter Maaten, J. M., Sale, M. E., de Boer, R. A., & Pitt, B. (2018). Subcutaneous furosemide in heart failure: Pharmacokinetic characteristics of a newly buffered solution. JACC Basic Translational Science, 3(1), 25\u201334. https:\/\/doi.org\/10.1016\/j.jacbts.2017.10.001","journal-title":"JACC Basic Translational Science"},{"issue":"1","key":"10173_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2017.10.001","volume":"6","author":"NA Gilotra","year":"2018","unstructured":"Gilotra, N. A., Princewill, O., Marino, B., Okwuosa, I. S., Chasler, J., Almansa, J., Cummings, A., Rhodes, P., Chambers, J., Cuomo, K., & Russell, S. D. (2018). Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Failure, 6(1), 65\u201370. https:\/\/doi.org\/10.1016\/j.jchf.2017.10.001","journal-title":"JACC Heart Failure"},{"issue":"1","key":"10173_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40635-020-00311-5","volume":"8","author":"S Hammond","year":"2020","unstructured":"Hammond, S., Wignell, A., Cooling, P., Barrett, D. A., & Davies, P. (2020). Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medicine Experimental, 8(1), 25. https:\/\/doi.org\/10.1186\/s40635-020-00311-5","journal-title":"Intensive Care Medicine Experimental"},{"issue":"5","key":"10173_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1939-1676.2003.tb02508.x","volume":"17","author":"DB Adin","year":"2003","unstructured":"Adin, D. B., Hill, R. C., & Scott, K. C. (2003). Short-term compatibility of furosemide with crystalloid solutions. Journal of Veterinary Internal Medicine, 17(5), 724\u2013726. https:\/\/doi.org\/10.1111\/j.1939-1676.2003.tb02508.x","journal-title":"Journal of Veterinary Internal Medicine"},{"issue":"5","key":"10173_CR16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ejhf.1428","volume":"21","author":"J Biegus","year":"2019","unstructured":"Biegus, J., Zymli\u0144ski, R., Sokolski, M., Todd, J., Cotter, G., Metra, M., Jankowska, E. A., Banasiak, W., & Ponikowski, P. (2019). Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. European Journal of Heart Failure, 21(5), 624\u2013633. https:\/\/doi.org\/10.1002\/ejhf.1428","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10173_CR17","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ehf2.13372","volume":"8","author":"J Biegus","year":"2021","unstructured":"Biegus, J., Zymli\u0144ski, R., Fudim, M., Testani, J., Sokolski, M., Marciniak, D., Ponikowska, B., Guzik, M., Garus, M., Urban, S., & Ponikowski, P. (2021). Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Heart Failure, 8(4), 2597\u20132602. https:\/\/doi.org\/10.1002\/ehf2.13372","journal-title":"ESC Heart Failure"},{"issue":"11","key":"10173_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jchf.2016.06.007","volume":"4","author":"J N\u00fa\u00f1ez","year":"2016","unstructured":"N\u00fa\u00f1ez, J., Ll\u00e0cer, P., Bertomeu-Gonz\u00e1lez, V., Bosch, M. J., Merlos, P., Garc\u00eda-Blas, S., Montagud, V., Bod\u00ed, V., Bertomeu-Mart\u00ednez, V., Pedrosa, V., Mendiz\u00e1bal, A., Cordero, A., Gallego, J., Palau, P., Mi\u00f1ana, G., Santas, E., Morell, S., Ll\u00e0cer, A., Chorro, F. J., & Sanchis, J. (2016). F\u00e1cila L; CHANCE-HF Investigators. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: A randomized study. JACC Heart Failure, 4(11), 833\u2013843. https:\/\/doi.org\/10.1016\/j.jchf.2016.06.007","journal-title":"JACC Heart Failure"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-021-10173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-021-10173-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-021-10173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:28:33Z","timestamp":1655818113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-021-10173-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10173"],"URL":"https:\/\/doi.org\/10.1007\/s12265-021-10173-1","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Rafael de la Espriella received board speaker fees and travel expenses from Novartis, Rovi, Pfizer, Daiichi Sankyo, Astra-Zeneca, NovoNordisk, Boehringer Ingelheim, Lilly. Gema Mi\u00f1ana received speaker fees and travel expenses from Abbott. Enrique Santas received board speaker fees and travel expenses from Novartis, Rovi, Pfizer, Daiichi Sankyo, Astra-Zeneca, NovoNordisk, Boehringer Ingelheim. Julio N\u00fa\u00f1ez received board speaker fees and travel expenses from Novartis, Rovi, Pfizer, Daiichi Sankyo, Astra-Zeneca, NovoNordisk, Boehringer Ingelheim, Lilly. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}